J Stroke.  2021 Jan;23(1):128-131. 10.5853/jos.2020.03650.

Cilostazol and Probucol for Cognitive Decline after Stroke: A Cognitive Outcome Substudy of the PICASSO Trial

• Lim JS
• Kwon SU
• Yu KH
• Yu S
• Park JH
• Lee BC
• Oh MS
• Kim YJ
• Rha JH
• Hwang YH
• Lee JS
• Heo SH
• Ahn SH
• Seo WK
• Park JM
• Lee JH
• Kwon JH
• Sohn SI
• Jung JM
• Kim HY
• Kim EG
• Cha JK
• Park MS
• Nam HS
• Bae HJ
• Kim DE
• Park J
• Kang Y
• Choi J
• Lee J

• KMID: 2512362
• DOI: http://doi.org/10.5853/jos.2020.03650

Figure

• 

  Figure 1. Mean changes in cognitive scores from baseline to each follow-up in (A, B) cilostazol vs. aspirin and (C, D) probucol vs. no probucol groups. (A, C) Mini-Mental State Examination (MMSE) and (B, D) Montreal Cognitive Assessment (MoCA).

Reference

References

1. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008; 7:875–884.

2. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014; 13:1177–1185.

3. Ihara M, Nishino M, Taguchi A, Yamamoto Y, Hattori Y, Saito S, et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. PLoS One. 2014; 9:e89516.

4. Park SH, Kim JH, Bae SS, Hong KW, Lee DS, Leem JY, et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. Biochem Biophys Res Commun. 2011; 408:602–608.

5. Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL, et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. Exp Neurol. 2012; 233:767–775.

6. Kim BJ, Lee EJ, Kwon SU, Park JH, Kim YJ, Hong KS, et al. Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurol. 2018; 17:509–518.

7. Yu KH, Hong KS, Oh MS, Lee J, Lee JS, Kwon SU, et al. Design and rationale for a cognitive outcome substudy in ischemic stroke patients with high risk of cerebral hemorrhage. J Stroke Cerebrovasc Dis. 2016; 25:2061–2066.

8. Jokinen H, Kalska H, Mäntylä R, Ylikoski R, Hietanen M, Pohjasvaara T, et al. White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. J Neurol Neurosurg Psychiatry. 2005; 76:1229–1233.

9. Jacova C, Pearce LA, Costello R, McClure LA, Holliday SL, Hart RG, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012; 72:351–362.

10. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003; 34:2323–2330.

11. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010; 9:689–701.

12. Sachdev PS, Lo JW, Crawford JD, Mellon L, Hickey A, Williams D, et al. STROKOG (stroke and cognition consortium): an international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. Alzheimers Dement (Amst). 2016; 7:11–23.